Myricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform
Myricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform
• Potential first-in-class N-myristoyltransferase inhibitor (NMTi) ADC payload with a differentiated mechanism of action
• Combines oncology expertise of Novartis with Myricx Bio’s novel ADC assets and platform having broad potential across multiple solid tumour types
• Transaction valued at up to $1.5 billion including $1.1 billion cash upfront


